Evidence map›Paper›PMID 29742799›Full record

ArticleHippocampus2018

Hippocampal place cell dysfunction and the effects of muscarinic M

Claire R Galloway, Kaushik Ravipati, Suyashi Singh, Evan P Lebois, Robert M Cohen, Allan I Levey, Joseph R Manns

Abstract read
In one paragraph

Article in Hippocampus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Claire R GallowayDepartment of Psychology, Emory University, Atlanta, Georgia.
Kaushik RavipatiNeuroscience and Behavioral Biology Program, Emory University, Atlanta, Georgia.
Suyashi SinghNeuroscience and Behavioral Biology Program, Emory University, Atlanta, Georgia.
Evan P LeboisInternal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Robert M CohenDepartment of Psychiatry, Emory University, Atlanta, Georgia.
Allan I LeveyDepartment of Neurology, Emory University, Atlanta, Georgia.
Joseph R MannsDepartment of Psychology, Emory University, Atlanta, Georgia.ORCID 0000-0002-1328-2145
Emory University · USPfizer (United States) · US

Funding

A Novel M1 muscarinic activator to treat memory deficits in Alzheimer's DiseaseR21AG042730 · NIA · EMORY UNIVERSITY · PI MANNS, JOSEPH R · 2013 to 2014
$425k
NIA NIH HHS R21 AG042730
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that disproportionately impacts memory and the hippocampus. However, it is unclear how AD pathology influences the activity of surviving neurons in the hippocampus to contribute to the memory symptoms in AD. One well-understood connection between spatial memory and neuronal activity in healthy brains is the activity of place cells, neurons in the hippocampus that fire preferentially in a specific location of a given environment (the place field of the place cell). In the present study, place cells were recorded from the hippocampus in a recently-developed rat model of AD (Tg-F344 AD) at an age (12-20 months) at which the AD rats showed marked spatial memory deficits. Place cells in the CA2 and CA3 pyramidal regions of the hippocampus in AD rats showed sharply reduced spatial fidelity relative to wild-type (WT) rats. In contrast, spiking activity of place cells recorded in region CA1 in AD rats showed good spatial fidelity that was similar to CA1 place cells in WT rats. Oral administration of the M

Indexed as

Action PotentialsAge FactorsAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsBenzamidesBiphenyl CompoundsDisease Models, AnimalFemaleHippocampusMemory DisordersMutationNeuronsPresenilin-1RatsRats, Inbred F344Amyloid beta-Protein PrecursorBenzamidesBiphenyl CompoundsPresenilin-1PSEN1 protein, humanReceptor, Muscarinic M1VU0364572acetylcholineCA1CA3dementiamemory

Identifiers

PMID29742799
PMCPMC6133736
OpenAlexW2801277693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.